The growing prevalence of hepatitis, particularly hepatitis B, is significantly influencing the North America Hepatitis Delta Virus (HDV) infection market. Hepatitis D is a liver infection caused by the Hepatitis D Virus (HDV), which requires the presence of the Hepatitis B Virus (HBV) to replicate. As hepatitis B infections increased regionally, the number of individuals susceptible to HDV infection also rises. This growing pool of HBV-infected individuals creates a larger target population for HDV, thus driving demand for diagnostic and therapeutic solutions specific to HDV.
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER FIVE FORCES
4.3 NORTH AMERICA CLINICAL TRIAL MARKET FOR NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
4.4 DISTRIBUTION OF PRODUCTS BY PHASE
5 EPIDEMIOLOGY
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING PREVALENCE OF HEPATITIS
6.1.2 INCREASE IN HEALTHCARE EXPENDITURE
6.1.3 ONGOING RESEARCH AND DEVELOPMENT INITIATIVES
6.1.4 ADVANCES IN DIAGNOSTIC TECHNOLOGIES
6.2 RESTRAINTS
6.2.1 LIMITED AWARENESS OF HEPATITIS DELTA VIRUS (HDV)
6.2.2 HIGH COST OF TREATMENT
6.3 OPPORTUNITIES
6.3.1 RISING INNOVATIVE DRUG DEVELOPMENT
6.3.2 INCREASING DEVELOPMENT OF COMBINATION THERAPIES
6.3.3 GROWING ADVANCEMENTS IN DIGITAL HEALTH SOLUTIONS
6.4 CHALLENGES
6.4.1 SIDE EFFECTS OF CURRENT TREATMENTS
6.4.2 SLOW REGULATORY APPROVALS
7 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE
7.1 OVERVIEW
7.2 ACUTE HEPATITIS D
7.3 CHRONIC HEPATITIS D
8 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 SURGERY (LIVER TRANSPLANT)
8.3 MEDICATION
8.3.1 APPROVED THERAPIES
8.3.1.1 PEGYLATED INTERFERON ALPHA
8.3.1.2 ENTRY INHIBITOR (BULEVIRTIDE)
8.3.2 EMERGING THERAPIES
9 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM
9.1 OVERVIEW
9.2 TABLET
9.3 CAPSULE
9.4 INJECTABLE
10 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 BRANDED
10.3 GENERIC
11 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.2.1 TABLET
11.2.2 CAPSULE
11.2.3 OTHERS
11.3 PARENTERAL
12 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER
12.1 OVERVIEW
12.2 FEMALE
12.3 MALE
13 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULTS
13.3 GERIATRIC
13.4 PEDIATRIC
14 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION
14.1 OVERVIEW
14.2 CONTAMINATED NEEDLES
14.3 EXPOSURE TO INFECTED BLOOD
14.4 BLOOD AND PLASMA PRODUCT TRANSFUSION
14.5 OTHERS
15 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CENTERS
15.4 HOME CARE SETTING
15.5 RESEARCH INSTITUTES & ACADEMIC CENTERS
15.6 AMBULATORY SURGICAL CENTERS
15.7 OTHERS
16 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
16.3.1 HOSPITAL PHARMACY
16.3.2 RETAIL PHARMACY
16.3.3 ONLINE PHARMACY
16.4 OTHERS
17 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION
17.1 NORTH AMERICA
17.1.1 U.S.
17.1.2 CANADA
17.1.3 MEXICO
18 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 GILEAD SCIENCES, INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PIPELINE PRODUCT
20.1.5 RECENT DEVELOPMENTS
20.2 GENENTECH, INC.
20.2.1 COMPANY SNAPSHOT
20.2.2 PRODUCT PORTFOLIO
20.2.3 RECENT DEVELOPMENT
20.3 ALNYLAM PHARMACEUTICALS, INC.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PIPELINE PRODUCT
20.3.4 RECENT DEVELOPMENTS
20.4 ASSEMBLY BIOSCIENCES, INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 PIPELINE PRODUCT
20.4.4 RECENT DEVELOPMENTS
20.5 EIGER BIOPHARMACEUTICALS
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 PIPELINE PRODUCT
20.5.6 RECENT DEVELOPMENT
20.6 GLOBEIMMUNE INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 PIPELINE PRODUCT
20.6.3 RECENT DEVELOPMENT
20.7 HUAHUI HEALTH LTD.
20.7.1 COMPANY SNAPSHOT
20.7.2 PIPELINE PRODUCT
20.7.3 RECENT DEVELOPMENT
20.8 JOHNSON & JOHNSON SERVICES, INC.
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PIPELINE PRODUCT
20.8.4 RECENT DEVELOPMENT
20.9 PHARMAESSENTIA CORPORATION
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PIPELINE PRODUCT
20.9.4 RECENT DEVELOPMENT
20.1 REPLICOR
20.10.1 COMPANY SNAPSHOT
20.10.2 PIPELINE PRODUCT
20.10.3 RECENT DEVELOPMENTS
20.11 VIR BIOTECHNOLOGY, INC.
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE ANALAYSIS
20.11.3 PRODUCT PIPELINE
20.11.4 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
List of Table
TABLE 1 EMERGING NOVEL THERAPIES FOR HDV
TABLE 2 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 3 NORTH AMERICA ACUTE HEPATITIS D IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 4 NORTH AMERICA CHRONIC HEPATITIS D IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 6 NORTH AMERICA SURGERY (LIVER TRANSPLANT) IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 7 NORTH AMERICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 8 NORTH AMERICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 9 NORTH AMERICA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 10 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 11 NORTH AMERICA TABLET IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 12 NORTH AMERICA CAPSULE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 13 NORTH AMERICA INJECTABLE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 15 NORTH AMERICA BRANDED IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 16 NORTH AMERICA GENERIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 17 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 18 NORTH AMERICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 NORTH AMERICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 20 NORTH AMERICA PARENTERAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 22 NORTH AMERICA FEMALE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 NORTH AMERICA MALE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 25 NORTH AMERICA ADULTS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 NORTH AMERICA GERIATRIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 27 NORTH AMERICA PEDIATRIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 29 NORTH AMERICA CONTAMINATED NEEDLES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 NORTH AMERICA EXPOSURE TO INFECTED BLOOD IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 31 NORTH AMERICA BLOOD AND PLASMA PRODUCT TRANSFUSION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 32 NORTH AMERICA OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 34 NORTH AMERICA HOSPITALS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 35 NORTH AMERICA SPECIALTY CLINICS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 NORTH AMERICA HOME CARE SETTING IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 NORTH AMERICA RESEARCH INSTITUTES AND ACADEMIC CENTERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 38 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 39 NORTH AMERICA OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 41 NORTH AMERICA DIRECT TENDER IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 42 NORTH AMERICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 NORTH AMERICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 44 NORTH AMERICA OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 47 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 48 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 49 NORTH AMERICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 50 NORTH AMERICA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 51 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 53 NORTH AMERICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 55 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 56 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 57 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 58 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 59 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 60 NORTH AMERICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 61 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 62 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 63 U.S. MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 64 U.S. APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 66 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 67 U.S. ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 69 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 70 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 71 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 72 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 73 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 74 U.S. RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 75 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 77 CANADA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 78 CANADA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 80 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 81 CANADA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 83 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 84 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 85 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 86 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 87 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 88 CANADA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 89 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 91 MEXICO MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 MEXICO APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 94 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 95 MEXICO ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 97 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 98 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 99 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 100 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 101 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 102 MEXICO RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
List of Figure
FIGURE 1 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SEGMENTATION
FIGURE 11 TWO SEGMENTS COMPRISE THE NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE
FIGURE 12 GROWING PREVALENCE OF HEPATITIS IS DRIVING THE GROWTH OF THE NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET FROM 2024 TO 2031
FIGURE 13 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET IN 2024 AND 2031
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
FIGURE 15 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, 2023
FIGURE 16 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 17 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 18 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, 2023
FIGURE 20 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, 2024-2031 (USD THOUSAND)
FIGURE 21 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 22 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 23 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, 2023
FIGURE 24 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND)
FIGURE 25 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, CAGR (2024-2031)
FIGURE 26 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 27 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, 2023
FIGURE 28 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)
FIGURE 29 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 30 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 31 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 32 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)
FIGURE 33 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 34 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER,2023
FIGURE 36 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, 2024-2031 (USD THOUSAND)
FIGURE 37 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, CAGR (2024-2031)
FIGURE 38 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, 2023
FIGURE 40 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, 2024-2031 (USD THOUSAND)
FIGURE 41 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 42 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 43 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, 2023
FIGURE 44 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, 2024-2031 (USD THOUSAND)
FIGURE 45 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, CAGR (2024-2031)
FIGURE 46 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, LIFELINE CURVE
FIGURE 47 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, 2023
FIGURE 48 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 49 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, CAGR (2024-2031)
FIGURE 50 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, LIFELINE CURVE
FIGURE 51 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 52 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 53 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 54 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 55 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SNAPSHOT (2023)
FIGURE 56 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY SHARE 2023 (%)